Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Sepracor Inc.

(SEPR)

Volpe, Welty analyst David Steinberg raised his yearend price

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE